title: Iron promotes DEN initiated GST-P foci in rat liver.
abstract: Diethylnitrosamine (DEN) was administered to rats as a single dose, which is known not to give rise to liver tumours without subsequent promotion. Iron dextran (Fe/Dex) was then administered parenterally to the animals, to induce iron overload. At 3 and 6 months after the final Fe/Dex treatments, livers were examined quantitatively for the numbers of the placental form of glutathione-S-transferase (GST-P) expressing foci, the area occupied by these foci and their size distribution. The results demonstrate that iron not only increased the number of foci after DEN initiation in the rat liver, but that the area occupied by these lesions increased significantly between 3 and 6 months after initiation. There is no evidence that iron increased the number of GST-P expressing foci present in rats not exposed to DEN. This indicates that iron did not act as an initiator in this rodent model of liver cancer. The increase in the area of the liver occupied by the foci in iron and DEN treated rats was due to an increase in the size of the foci, as well as to an increase in the number of foci. This is the first demonstration that iron can act as a promoter of DEN initiated hepatocytes. It also demonstrates that fibrogenesis is not an absolute requirement for the promotion, by iron, of liver foci in the rat, and that this could also be the case for iron overload in man. Iron may also act as a promoter of already initiated hepatocytes in the development of human liver cancer, as it does in the rat.
authors.affiliation: MRC Toxicology Unit, University of Leicester, UK.
authors.forename: P
authors.initials: P
authors.lastname: Carthew
authors.forename: B M
authors.initials: BM
authors.lastname: Nolan
authors.forename: A G
authors.initials: AG
authors.lastname: Smith
authors.forename: R E
authors.initials: RE
authors.lastname: Edwards
mesh_terms: D000818:Animals; D015415:Biomarkers; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity*; D056486:Chemical and Drug Induced Liver Injury; D004052:Diethylnitrosamine / Q000494:pharmacology / Q000633:toxicity*; D004357:Drug Synergism; D005260:Female; D005982:Glutathione Transferase / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D007501:Iron / Q000633:toxicity*; D019190:Iron Overload / Q000150:complications / Q000209:etiology; D007505:Iron-Dextran Complex / Q000494:pharmacology / Q000633:toxicity; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000150:complications; D008107:Liver Diseases / Q000201:enzymology / Q000209:etiology; D008954:Models, Biological; D009929:Organ Size / Q000187:drug effects; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000201:enzymology / Q000209:etiology; D051381:Rats; D011916:Rats, Inbred F344; D013045:Species Specificity
chemical_list: D015415:Biomarkers; D002273:Carcinogens; D004052:Diethylnitrosamine; D007505:Iron-Dextran Complex; D007501:Iron; D005982:Glutathione Transferase